# US 2015/0148347 A1 · Indanyloxyphenylcyclopropanecarboxylic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148347 A1
- Document ID: US20150148347A1
- Status: Published application
- Kind: A1
- Application number: 14/552,515
- Filed: 2014-11-25
- Published: 2015-05-28
- Earliest claimed: 2013-11-28
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Iain LINGARD; Dieter HAMPRECHT
- Web page: https://patentgrep.com/patent/US20150148347A1

## CPC

- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/195: having an amino group
- A61K 31/351: not condensed with another ring
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 62/34: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 65/26: containing rings other than six-membered aromatic rings
- C07C 235/46: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 235/48: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 255/54: containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
- C07C 317/18: with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C 317/22: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07D 213/61: Halogen atoms or nitro radicals
- C07D 213/62: Oxygen or sulfur atoms
- C07D 213/64: attached in position 2 or 6
- C07D 215/20: Oxygen atoms
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 257/04: Five-membered rings
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D 295/088: to an acyclic saturated chain
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/18: by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 295/192: from aromatic carboxylic acids
- C07D 309/10: Oxygen atoms
- C07D 309/12: only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
- C07D 309/14: Nitrogen atoms not forming part of a nitro radical
- C07C 2601/02: with a three-membered ring
- C07C 2602/02: the rings having only two atoms in common
- C07C 2602/08: the other ring being five-membered, e.g. indane
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

## Claims

### Claim 1

A compound of formula (I)
wherein:
R1 is selected from the group consisting of a phenyl ring, a tetrazolyl ring,
a 5-membered heteroaromatic ring containing 1 —NH—, —O—, or —S— group,
a 5-membered heteroaromatic ring containing 1 —NH—, —O—, or —S— group and additionally 1 or 2=N— atoms,
a 6-membered heteroaromatic ring containing 1, 2 or 3=N— atoms,
wherein optionally a second ring is annulated to the phenyl ring or to the 5- or 6-membered heteroaromatic rings and the second ring is 5- or 6-membered, unsaturated or aromatic and optionally contains 1, 2, or 3 heteroatoms independently selected from ═N—, —NH—, —O—, and —S— with the proviso that only up to two of the heteroatoms are O and S and no O—O, S—S, and S—O bond is formed, and wherein in the second ring independently of the presence of heteroatoms 1 or 2 CH2 groups are optionally replaced by —C(O)—, —S(O)—, or —S(O)2—,
wherein the phenyl ring, tetrazolyl ring, 5- or 6-membered heteroaromatic ring, annulated phenyl ring, and annulated 5- or 6-membered heteroaromatic ring are optionally substituted at a carbon atom with one group R1a, and
wherein the phenyl ring, tetrazolyl ring, 5- or 6-membered heteroaromatic ring, annulated phenyl ring, and annulated 5- or 6-membered heteroaromatic ring are optionally additionally substituted at carbon atoms with 1 to 3 groups independently selected from R1b, and
wherein the H-atom in one or more NH groups present in the tetrazolyl ring, 5- or 6-membered heteroaromatic ring, annulated phenyl ring, or annulated 5- or 6-membered heteroaromatic ring optionally is replaced by RM;
R2 is F, Cl, Br, I, C1-4-alkyl, C3-6-cycloalkyl, NC—, H2N—C(O)—, C1-4-alkyl-NRM—C(O)—, C1-4-alkyloxy, or C1-4-alkyl-S(O)2—, wherein any alkyl and cycloalkyl group or sub-group thereof is optionally substituted with one or more F atoms, and wherein multiple R2 are identical or different, if m is 2 or 3;
R3 is F, Cl, Br, NC—, C1-6-alkyl, C3-6-cycloalkyl-, C1-6-alkyl-O—, or C3-6-cycloalkyl-O—, wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group thereof is optionally substituted with one or more F atoms;
X is —O—, >S═O, >S(═O)2, —CH2—, or —S—;
m is 0, 1, 2, or 3;
n is 0, 1, or 2;
R1a is selected from the group consisting of C1-6-alkyl, C2-6-alkenyl, C2-6-alkinyl, C3-6-cycloalkyl-, C3-6-cycloalkyl-C1-6-alkyl, C1-4-alkyl-NH—, (C1-4-alkyl)2N—, —NHRN, HNRM—C(O)—, C1-4-alkyl-NRM—C(O)—, C1-6-alkyl-O—, C3-6-cycloalkyl-O—, C3-6-cycloalkyl-C1-6-alkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(O)—, C1-4-alkyl-S(O)2, and aryl-C1-3-alkyl-O—,
wherein a —CH2— member within a C4-6-cycloalkyl- group or sub-group within the groups thereof is optionally replaced by —NRN—, —O—, —S—, —S(O)—, or —S(O2)—, or
wherein a >CH—CH2— member or a —CH2—CH2— member within a C5-6-cycloalkyl-group or sub-group within the groups thereof is optionally replaced by >N—C(O)—, >N—S(O)—, >N—S(O)2—, —N(RM)—C(O)—, —N(RM)—S(O)—, or —N(RM)—S(O)2—, and
wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups thereof is optionally substituted with HO—, HO—C1-4-alkyl-, C1-4-alkyl-oxy, C1-4-alkyl-oxy-C1-4-alkyl-, C1-4-alkyl-sulfanyl, C1-4-alkyl-sulfinyl, C1-4-alkyl-sulfonyl, H2N—C(O)—, C1-4-alkyl-NH—C(O)—, (C1-4-alkyl)2N—C(O)—, or C3-6-cycloalkyl-NRM—C(O)—, and/or optionally substituted with one or more F atoms,
a phenyl ring, a tetrazolyl ring,
a 5-membered heteroaromatic ring containing 1 —NH—, —O—, or —S— group,
a 5-membered heteroaromatic ring containing 1 —NH—, —O—, or —S— group and additionally 1 or 2=N— atoms,
a 6-membered heteroaromatic ring containing 1, 2, or 3=N— atoms,
wherein the rings are optionally substituted with one or more groups selected from R1b, and
wherein the H-atom in one or more NH groups present in the tetrazolyl ring or 5-membered heteroaromatic ring is replaced by RM;
R1b is F, Cl, CN, —OH, C1-4-alkyl, C3-6-cycloalkyl-, HO—C1-4-alkyl, C1-4-alkyl-O—C1-4-alkyl, C1-4-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-O—C1-4-alkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(O)—, or C1-4-alkyl-S(O)2—, wherein any alkyl and cycloalkyl group or sub-group within the groups thereof is optionally substituted with one or more F atoms;
RN is independently H, C1-4-alkyl, HO—C2-4-alkyl (with the proviso that at least 2 carbon atoms are between the HO-group and an NH), C1-4-alkyl-O—C2-4-alkyl-(with the proviso that at least 2 carbon atoms are between an O-group and an NH), C1-4-alkyl-C(O)—, C1-4-alkyl-O—C(O)—, or C1-4-alkyl-S(O)2—, wherein any alkyl group or sub-group within the groups thereof is optionally substituted with one or more F atoms; and
RM is independently H, C1-4-alkyl, HO—C2-4-alkyl (with the proviso that at least 2 carbon atoms are between the HO-group and an NH), or C1-4-alkyl-O—C2-4-alkyl-(with the proviso that at least 2 carbon atoms are between an O-group and an NH), wherein any alkyl group or sub-group within the groups thereof is optionally substituted with one or more F atoms, or
a salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
R1 is selected from the group consisting of
a phenyl ring, a tetrazolyl ring,
a 5-membered heteroaromatic ring containing 1 —NH— or —O— group,
a 5-membered heteroaromatic ring containing 1 —NH— or —O— group and additionally 1 or 2=N— atoms,
a 6-membered heteroaromatic ring containing 1, 2, or 3=N— atoms,
wherein the phenyl ring, tetrazolyl ring, and 5- or 6-membered heteroaromatic ring are optionally substituted at a carbon atom with one group R1a, and
wherein the phenyl ring, tetrazolyl ring, 5- or 6-membered heteroaromatic ring are optionally additionally substituted at carbon atoms with 1 to 3 groups independently selected from R1b, and
wherein the H-atom in one or more NH groups present in the tetrazolyl ring, 5- or 6-membered heteroaromatic ring optionally is replaced by RM;
X is —O—, >S═O, >S(═O)2, or —CH2—;
m is 1 or 2;
n is 0 or 1;
R1a is selected from the group consisting of C1-4-alkyl, C2-4-alkenyl, C2-4-alkinyl, C3-6-cycloalkyl-, C3-6-cycloalkyl-C1-4-alkyl, C1-4-alkyl-NH—, (C1-4-alkyl)2N—, —NHRN, HNRM—C(O)—, C1-4-alkyl-NRM—C(O)—, C1-6-alkyl-O—, C3-6-cycloalkyl-O—, C3-6′ cycloalkyl-C1-4-alkyl-O—, C1-4-alkyl-S(O)2, and aryl-C1-3-alkyl-O—,
wherein a —CH2— member within a C4-6-cycloalkyl- group or sub-group within the groups thereof is optionally replaced by —NRN—, —O—, or —S(O2)—, or
wherein a >CH—CH2— member or a —CH2—CH2— member within a C5-6-cycloalkyl-group or sub-group within the groups thereof is optionally replaced by >N—C(O)—, >N—S(O)2—, —N(RM)—C(O)—, or —N(RM)—S(O)2—, and
wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups thereof is optionally substituted with HO—, HO—C1-3-alkyl-, C1-3-alkyl-oxy, C1-3-alkyloxy-O1-4-alkyl-, C1-4-alkyl-sulfonyl, H2N—C(O)—, C1-4-alkyl-NH—C(O)—, or (C1-4-alkyl)2N—C(O)—, and/or optionally substituted with 1 to 3 F atoms;
R1b is F, Cl, CN, —OH, C1-3-alkyl, C3-6-cycloalkyl-, HO—C1-3-alkyl, C1-3-alkyl-O—, or C3-6-cycloalkyl-O—, wherein any alkyl and cycloalkyl group or sub-group within the groups thereof is optionally substituted with 1 to 3 F atoms;
RN is H, C1-4-alkyl, HO—C1-4-alkyl (with the proviso that at least 2 carbon atoms are between the HO-group and an NH), C1-4-alkyl-C(O)—, C1-3-alkyl-O—C(O)—, or C1-3-alkyl-S(O)2—, wherein any alkyl group or sub-group within the groups thereof is optionally substituted with 1 to 3 F atoms; and
RM is H, C1-3-alkyl, HO—C2-4-alkyl (with the proviso that at least 2 carbon atoms are between the HO-group and an NH), or C1-3-alkyl-O—C2-3-alkyl-(with the proviso that at least 2 carbon atoms are between an O-group and an NH), wherein any alkyl group or sub-group within the groups thereof is optionally substituted with 1 to 5 F atoms, or
a salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein
R1a is selected from the group consisting of
a phenyl ring, a tetrazolyl ring,
a 5-membered heteroaromatic ring containing 1 —NH— or —O— group,
a 5-membered heteroaromatic ring containing 1 —NH— or —O— group and additionally 1 or 2=N— atoms,
a 6-membered heteroaromatic ring containing 1 or 2=N— atoms,
wherein the rings are optionally substituted with one to three groups selected from R1b, and
wherein the H-atom in one or more NH groups present in the tetrazolyl ring or 5-membered heteroaromatic ring is replaced by RM, or
a salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein:
R2 is F, Cl, Br, I, C1-3-alkyl, C3-6-cycloalkyl, NC—, H2N—C(O)—, or C1-3-alkyloxy, wherein any alkyl and cycloalkyl group or sub-group within the groups thereof is optionally substituted with 1 to 3 F atoms, and wherein multiple R2 are identical or different, if m is 2 or 3; and
X is —O—, >S═O, >S(═O)2, and —CH2—, or
a salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein:
R3 is F, Cl, Br, NC—, C1-4-alkyl, C3-6-cycloalkyl-, C1-4-alkyl-O—, or C3-6-cycloalkyl-O—, wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups thereof is optionally substituted with 1 to 3 F atoms; and
X is —O—, >S═O, >S(═O)2, and —CH2—, or
a salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1 and selected from embodiments E2 to E44 disclosed in table 1, or a salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein the compound has the stereochemistry shown in formula I.1 or I.2
or a salt thereof.

### Claim 8 (depends on 1)

A pharmaceutically acceptable salt of a compound according to claim 1.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and an inert carrier or diluent.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, further comprising an additional therapeutic agent.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the additional therapeutic agent is an antidiabetic agent, an agent for the treatment of overweight and/or obesity, or an agent for the treatment of high blood pressure, heart failure, and/or atherosclerosis.

### Claim 12 (depends on 1)

A method for treating a disease or condition which can be influenced by the modulation of the function of GPR40 in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound according to claim 1.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the disease or condition is a metabolic disease.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the disease or condition is type 2 diabetes mellitus, insulin resistance, obesity, cardiovascular disease, or dyslipidemia.
